The oral administration of Lacticaseibacillus casei Shirota alleviates acetaminophen-induced liver injury through accelerated acetaminophen metabolism via the liver-gut axis in mice
mSphere · 2024
DOI: 10.1128/msphere.00672-23 ↗Kurz gefasst
Fachartikel in der Zeitschrift mSphere, 2024. Verfasst von Longxian Lv und 8 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Di…. Hauptthemen laut MEDLINE: Lacticaseibacillus casei, Antipyretics, Chemical and Drug Induced Liver Injury, Chronic, Liver Failure. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 48 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: MOST | National Key Research and Development Program of China (NKPs), MOST | | Medical Science and Technology Project of Zhejiang Province (), MOST | 浙江省卫生厅 | Medical Science and Technology Project of Zhejiang Province.
Abstract (Originalsprache)
Acetaminophen is a widely used antipyretic and analgesic drug, and its overdose is the leading cause of drug-induced acute liver failure. This study aimed to investigate the effect and mechanism of Lacticaseibacillus casei Shirota (LcS), an extensively used and highly studied probiotic, on acetaminophen-induced acute liver injury. C57BL/6 mice were gavaged with LcS suspension or saline once daily for 7 days before acute liver injury was induced via intraperitoneal injection of 300 mg/kg acetaminophen. The results showed that LcS significantly decreased acetaminophen-induced liver and ileum injury, as demonstrated by reductions in the increases in aspartate aminotransferase, total bile acids, total bilirubin, indirect bilirubin, and hepatic cell necrosis. Moreover, LcS alleviated acetaminophen-induced intestinal mucosal permeability, decreased serum IL-1α and lipopolysaccharide levels, and elevated serum eosinophil chemokine (eotaxin) and hepatic glutathione levels. Furthermore, analysis of the gut microbiota and metabolome showed that LcS reduced the acetaminophen-enriched levels of Cyanobacteria , Oxyphotobacteria , long-chain fatty acids, cholesterol, and sugars in the gut. Additionally, the transcriptomic and proteomic results showed that LcS mitigated the decrease in metabolic and immune pathways as well as glutathione formation during acetaminophen-induced acute liver injury. This is the first study showing that pretreatment with LcS alleviates acetaminophen-enriched acute liver injury, and it provides a reference for the application of LcS. IMPORTANCE Acetaminophen is the most frequently used antipyretic analgesic worldwide. As a result, overdoses easily occur and lead to drug-induced acute liver injury, which quickly progresses to liver failure with a mortality of 60%–80% if not corrected in time. The current emergency treatment for overused acetaminophen needs to be administered within 8 hours to avoid liver injury or even liver failure. Therefore, developing preventive strategies for liver injury during planned acetaminophen medication is particularly important, preferably nonpharmacological methods. Lacticaseibacillus casei Shirota (LcS) is a famous probiotic that has been used for many years. Our study found that LcS significantly alleviated acetaminophen-induced acute liver injury, especially acetaminophen-induced liver injury toward fulminant hepatic failure. Here, we elucidated the function and potential mechanisms of LcS in alleviating acetaminophen-induced acute liver injury, hoping it will provide preventive strategies to people during acetaminophen treatment.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory for Diagnosis and Treatment of Infectious Diseases, Collaborative Innovation Center for Diagnosis and Treatment of Infectious Diseases, The First Affiliated Hospital, College of Medicine, Zhejiang U…
- Jinan Microecological Biomedicine Shandong Laboratory, Jinan, Shandong, China.
- Key Laboratory of Biomarkers and In Vitro Diagnosis Translation of Zhejiang Province, School of Public Health, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- School of Clinical Medicine, Hangzhou Medical College, Hangzhou, Zhejiang, China.
- The Affiliated Hospital of Hangzhou Normal University, Institute of Translational Medicine, Hangzhou Normal University, Hangzhou, Zhejiang, China.
ORCID-Profile: Longxian Lv, Li Shao, Ying Yu
Förderung
- MOST | National Key Research and Development Program of China (NKPs)
- MOST | | Medical Science and Technology Project of Zhejiang Province ()
- MOST | 浙江省卫生厅 | Medical Science and Technology Project of Zhejiang Province
Zitieren
APA
Lv, L., Ren, S., Jiang, H., Yan, R., Chen, W., Yan, R., Dong, J., Shao, L., & Yu, Y. (2024). The oral administration of Lacticaseibacillus casei Shirota alleviates acetaminophen-induced liver injury through accelerated acetaminophen metabolism via the liver-gut axis in mice. mSphere. https://doi.org/10.1128/msphere.00672-23
Vancouver
Lv L, Ren S, Jiang H, Yan R, Chen W, Yan R, et al. The oral administration of Lacticaseibacillus casei Shirota alleviates acetaminophen-induced liver injury through accelerated acetaminophen metabolism via the liver-gut axis in mice. mSphere. 2024. doi:10.1128/msphere.00672-23
BibTeX
@article{Lv2024,
author = {Lv, Longxian and Ren, Siqi and Jiang, Huiyong and Yan, Ren and Chen, Wenyi and Yan, Ruiyi and Dong, Jinming and Shao, Li and Yu, Ying},
title = {The oral administration of Lacticaseibacillus casei Shirota alleviates acetaminophen-induced liver injury through accelerated acetaminophen metabolism via the liver-gut axis in mice},
journal = {mSphere},
year = {2024},
doi = {10.1128/msphere.00672-23}
}
EUVIMED